CTLA4 and cancer: The first study (phase 1b) evaluated the safety and efficacy of durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) combination in patients with advanced squamous or non-squamous NSCLC across five cancer centers in USA.